BIT Capital GmbH Acquires Shares of 21,468 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Key Points

• BIT Capital GmbH acquired a new stake in Agios Pharmaceuticals by purchasing 21,468 shares valued at approximately $629,000 in the first quarter.
• Agios Pharmaceuticals reported a quarterly EPS of ($1.93), missing analysts' expectations, despite revenues of $12.50 million which exceeded expectations of $9.46 million.
• Company insider transactions included significant stock sales, with Director David Scadden selling 1,400 shares at an average price of $40.00, reducing their ownership by 7.37%.

BIT Capital GmbH bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,468 shares of the biopharmaceutical company's stock, valued at approximately $629,000.

A number of other hedge funds have also recently modified their holdings of AGIO. Jefferies Financial Group Inc. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $49,290,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $9,957,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $9,084,000. Deutsche Bank AG boosted its holdings in shares of Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after buying an additional 265,637 shares in the last quarter. Finally, Casdin Capital LLC bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $8,215,000.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded down $0.22 during midday trading on Tuesday, hitting $35.95. 264,992 shares of the company's stock traded hands, compared to its average volume of 714,012. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 3.27 and a beta of 0.80. The firm has a fifty day moving average of $35.81 and a 200 day moving average of $32.60.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares of the company's stock, valued at approximately $876,131.88. This represents a 9.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brian Goff sold 18,700 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the completion of the sale, the chief executive officer directly owned 105,401 shares of the company's stock, valued at $3,535,149.54. This represents a 15.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 46,363 shares of company stock worth $1,619,654 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on AGIO shares. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank dropped their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research note on Monday, July 28th. Finally, Bank of America dropped their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.